Patently Innovative ：How Pharmaceutical Firms Use Emerging Patent Law to Extend Monopolies on Blockbuster Drugs ( Woodhead Publishing Series in Biomedicine )

Publication subTitle ：How Pharmaceutical Firms Use Emerging Patent Law to Extend Monopolies on Blockbuster Drugs

Publication series ：Woodhead Publishing Series in Biomedicine

Author： Bouchard   R A  

Publisher： Elsevier Science‎

Publication year： 2012

E-ISBN: 9781908818089

P-ISBN(Paperback): 9781907568121

P-ISBN(Hardback):  9781907568121

Subject： D90 theory of law (jurisprudence);D91 Legal departments;D923.4 intellectual property;R9 Pharmacy

Keyword： 普通生物学

Language： ENG

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Description

Patently innovative provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regulated and how government regulation can either stimulate or inhibit development of breakthrough products.

  • Includes empirical research to relate innovation to drug law
  • A multidisciplinary approach is taken, including the intersection of IP (intellectual property) law, drug law and innovation
  • Discusses the impact of government regulation on firm innovation

Chapter

Cover

Dedication

Patently innovative: How pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs

Copyright

Contents

Acknowledgements

List of figures and tables

List of abbreviations

About the author

1 Introduction

1.1 The emergence of global pharmaceutical linkage

1.2 Canadian pharmaceutical linkage regulations

1.3 Organization

Notes

2 Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy

2.1 Drug approval

2.2 Patents

2.3 Linkage regulations

2.4 IPR rights and innovation policy

Notes

3 Empirical analysis of drug approval

3.1 Introduction

3.2 Analysis

3.3 Results

3.4 Discussion

3.5 Interpretation of data

3.6 Study limitations

3.7 Assessing the lifecycle approach: the long view

3.8 Government as representative public agent

3.9 Summary and conclusions

Notes

4 Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage

4.1 Introduction

4.2 Methods

4.3 Results

4.4 Discussion

Notes

5 Empirical analysis of drug patenting in multiple high-value cohorts

5.1 Introduction

5.2 Methods

5.3 Results

5.4 Discussion

5.5 Summary and conclusions

Notes

6 Implications of empirical data: are pharmaceutical linkage regulations a success?

6.1 Introduction

6.2 Debate preceding Bill C-91

6.3 ‘Original policy intent’

6.4 ‘Patent-specific’ analysis

6.5 Statutory interpretation

6.6 Revisiting the empirical data

6.7 Summary and conclusions

Notes

7 Future directions: testable hypotheses and evolution toward global pharmaceutical linkage

7.1 Hypotheses regarding cluster-based drug development

7.2 Globalization of pharmaceutical linkage

Notes

Index

Cover

Dedication

Patently innovative: How pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs

Copyright

Contents

Acknowledgements

List of figures and tables

List of abbreviations

About the author

1 Introduction

2 Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy

3 Empirical analysis of drug approval

4 Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage

5 Empirical analysis of drug patenting in multiple high-value cohorts

6 Implications of empirical data: are pharmaceutical linkage regulations a success?

7 Future directions: testable hypotheses and evolution toward global pharmaceutical linkage

Index

The users who browse this book also browse


No browse record.